Media stories about Curis (NASDAQ:CRIS) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Curis earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.6022467672185 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of equities research analysts have recently weighed in on CRIS shares. Guggenheim started coverage on Curis in a research note on Monday, October 23rd. They set a “buy” rating and a $7.00 price target for the company. Zacks Investment Research downgraded Curis from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Curis has a consensus rating of “Hold” and a consensus target price of $6.50.
Shares of Curis (NASDAQ CRIS) traded up $0.03 during mid-day trading on Monday, hitting $0.55. The company had a trading volume of 1,030,000 shares, compared to its average volume of 1,580,000. The company has a debt-to-equity ratio of 1.24, a current ratio of 5.15 and a quick ratio of 5.15. Curis has a 1-year low of $0.48 and a 1-year high of $3.22. The company has a market cap of $90.26, a P/E ratio of -1.41 and a beta of 1.56.
In related news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The shares were acquired at an average cost of $1.06 per share, with a total value of $53,000.00. Following the purchase, the chief executive officer now owns 115,890 shares of the company’s stock, valued at $122,843.40. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.07% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Curis (CRIS) Stock Price” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-curis-cris-stock-price.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.